Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia

Dongfang Wang, Sunny Lihua Cheng, Qiang Fei, Haiwei Gu, Daniel Raftery, Bing Cao, Xiaoyu Sun, Jingjing Yan, Chuanbo Zhang, Jingyu Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Schizophrenia (SCZ) is a multifactorial psychiatric disorder. However, the molecular pathogenesis of SCZ remains largely unknown, and no reliable diagnostic test is currently available. Phospholipid metabolism is known to be disturbed during disease processes of SCZ. In this study, we used an untargeted liquid chromatography-mass spectrometry (LC-MS)-based metabolic profiling approach to measure lipid metabolites in serum samples from 119 SCZ patients and 109 healthy controls, to identify potential lipid biomarkers for the discrimination between SCZ patients and healthy controls. 51 lipid metabolites were identified to be significant for discriminating SCZ patients from healthy controls, including phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), phosphatidylethanolamines (PEs), lysophosphatidylethanolamines (LPEs) and sphingomyelins (SMs). Compared to healthy controls, most PCs and LPCs, as well as all PEs in patients were decreased, while most LPEs and all SMs were increased. A panel of six lipid metabolites could effectively discriminate SCZ patients from healthy controls with an area under the receiver-operating characteristic curve of 0.991 in the training samples and 0.980 in the test samples. These findings suggest that extensive disturbances of phospholipids may be involved in the development of SCZ. This LC-MS-based metabolic profiling approach shows potential for the identification of putative serum biomarkers for the diagnosis of SCZ.

Original languageEnglish (US)
Pages (from-to)18-29
Number of pages12
JournalPsychiatry Research
Volume272
DOIs
StatePublished - Feb 1 2019

Fingerprint

Phospholipids
Schizophrenia
Biomarkers
Serum
Phosphatidylethanolamines
Lipids
Lysophosphatidylcholines
Sphingomyelins
Phosphatidylcholines
Liquid Chromatography
Mass Spectrometry
Routine Diagnostic Tests
ROC Curve
Psychiatry

Keywords

  • Biomarker
  • Global metabolic profiling
  • Liquid chromatography-mass spectrometry
  • Metabolomics
  • Phospholipid
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia. / Wang, Dongfang; Cheng, Sunny Lihua; Fei, Qiang; Gu, Haiwei; Raftery, Daniel; Cao, Bing; Sun, Xiaoyu; Yan, Jingjing; Zhang, Chuanbo; Wang, Jingyu.

In: Psychiatry Research, Vol. 272, 01.02.2019, p. 18-29.

Research output: Contribution to journalArticle

Wang, D, Cheng, SL, Fei, Q, Gu, H, Raftery, D, Cao, B, Sun, X, Yan, J, Zhang, C & Wang, J 2019, 'Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia', Psychiatry Research, vol. 272, pp. 18-29. https://doi.org/10.1016/j.psychres.2018.12.008
Wang, Dongfang ; Cheng, Sunny Lihua ; Fei, Qiang ; Gu, Haiwei ; Raftery, Daniel ; Cao, Bing ; Sun, Xiaoyu ; Yan, Jingjing ; Zhang, Chuanbo ; Wang, Jingyu. / Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia. In: Psychiatry Research. 2019 ; Vol. 272. pp. 18-29.
@article{a7526f9e1eee4f06b47fe3a8dbae994c,
title = "Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia",
abstract = "Schizophrenia (SCZ) is a multifactorial psychiatric disorder. However, the molecular pathogenesis of SCZ remains largely unknown, and no reliable diagnostic test is currently available. Phospholipid metabolism is known to be disturbed during disease processes of SCZ. In this study, we used an untargeted liquid chromatography-mass spectrometry (LC-MS)-based metabolic profiling approach to measure lipid metabolites in serum samples from 119 SCZ patients and 109 healthy controls, to identify potential lipid biomarkers for the discrimination between SCZ patients and healthy controls. 51 lipid metabolites were identified to be significant for discriminating SCZ patients from healthy controls, including phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), phosphatidylethanolamines (PEs), lysophosphatidylethanolamines (LPEs) and sphingomyelins (SMs). Compared to healthy controls, most PCs and LPCs, as well as all PEs in patients were decreased, while most LPEs and all SMs were increased. A panel of six lipid metabolites could effectively discriminate SCZ patients from healthy controls with an area under the receiver-operating characteristic curve of 0.991 in the training samples and 0.980 in the test samples. These findings suggest that extensive disturbances of phospholipids may be involved in the development of SCZ. This LC-MS-based metabolic profiling approach shows potential for the identification of putative serum biomarkers for the diagnosis of SCZ.",
keywords = "Biomarker, Global metabolic profiling, Liquid chromatography-mass spectrometry, Metabolomics, Phospholipid, Schizophrenia",
author = "Dongfang Wang and Cheng, {Sunny Lihua} and Qiang Fei and Haiwei Gu and Daniel Raftery and Bing Cao and Xiaoyu Sun and Jingjing Yan and Chuanbo Zhang and Jingyu Wang",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.psychres.2018.12.008",
language = "English (US)",
volume = "272",
pages = "18--29",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia

AU - Wang, Dongfang

AU - Cheng, Sunny Lihua

AU - Fei, Qiang

AU - Gu, Haiwei

AU - Raftery, Daniel

AU - Cao, Bing

AU - Sun, Xiaoyu

AU - Yan, Jingjing

AU - Zhang, Chuanbo

AU - Wang, Jingyu

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Schizophrenia (SCZ) is a multifactorial psychiatric disorder. However, the molecular pathogenesis of SCZ remains largely unknown, and no reliable diagnostic test is currently available. Phospholipid metabolism is known to be disturbed during disease processes of SCZ. In this study, we used an untargeted liquid chromatography-mass spectrometry (LC-MS)-based metabolic profiling approach to measure lipid metabolites in serum samples from 119 SCZ patients and 109 healthy controls, to identify potential lipid biomarkers for the discrimination between SCZ patients and healthy controls. 51 lipid metabolites were identified to be significant for discriminating SCZ patients from healthy controls, including phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), phosphatidylethanolamines (PEs), lysophosphatidylethanolamines (LPEs) and sphingomyelins (SMs). Compared to healthy controls, most PCs and LPCs, as well as all PEs in patients were decreased, while most LPEs and all SMs were increased. A panel of six lipid metabolites could effectively discriminate SCZ patients from healthy controls with an area under the receiver-operating characteristic curve of 0.991 in the training samples and 0.980 in the test samples. These findings suggest that extensive disturbances of phospholipids may be involved in the development of SCZ. This LC-MS-based metabolic profiling approach shows potential for the identification of putative serum biomarkers for the diagnosis of SCZ.

AB - Schizophrenia (SCZ) is a multifactorial psychiatric disorder. However, the molecular pathogenesis of SCZ remains largely unknown, and no reliable diagnostic test is currently available. Phospholipid metabolism is known to be disturbed during disease processes of SCZ. In this study, we used an untargeted liquid chromatography-mass spectrometry (LC-MS)-based metabolic profiling approach to measure lipid metabolites in serum samples from 119 SCZ patients and 109 healthy controls, to identify potential lipid biomarkers for the discrimination between SCZ patients and healthy controls. 51 lipid metabolites were identified to be significant for discriminating SCZ patients from healthy controls, including phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), phosphatidylethanolamines (PEs), lysophosphatidylethanolamines (LPEs) and sphingomyelins (SMs). Compared to healthy controls, most PCs and LPCs, as well as all PEs in patients were decreased, while most LPEs and all SMs were increased. A panel of six lipid metabolites could effectively discriminate SCZ patients from healthy controls with an area under the receiver-operating characteristic curve of 0.991 in the training samples and 0.980 in the test samples. These findings suggest that extensive disturbances of phospholipids may be involved in the development of SCZ. This LC-MS-based metabolic profiling approach shows potential for the identification of putative serum biomarkers for the diagnosis of SCZ.

KW - Biomarker

KW - Global metabolic profiling

KW - Liquid chromatography-mass spectrometry

KW - Metabolomics

KW - Phospholipid

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85058654210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058654210&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2018.12.008

DO - 10.1016/j.psychres.2018.12.008

M3 - Article

VL - 272

SP - 18

EP - 29

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -